ECSP17021465A - Formulación que comprende glicopirrolato, método y aparato - Google Patents
Formulación que comprende glicopirrolato, método y aparatoInfo
- Publication number
- ECSP17021465A ECSP17021465A ECIEPI201721465A ECPI201721465A ECSP17021465A EC SP17021465 A ECSP17021465 A EC SP17021465A EC IEPI201721465 A ECIEPI201721465 A EC IEPI201721465A EC PI201721465 A ECPI201721465 A EC PI201721465A EC SP17021465 A ECSP17021465 A EC SP17021465A
- Authority
- EC
- Ecuador
- Prior art keywords
- glycopyrrolate
- magnesium stearate
- formulation including
- micronized
- including glycopyrrolate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describe un método para preparar una composición farmacéutica para administración pulmonar que comprende co-micronización de glicopirrolato y estearato de magnesio, en donde el glicopirrolato y el estearato de magnesio co-micronizados se someten posteriormente a una etapa de acondicionamiento que incluye la exposición del glicopirrolato y el estearato de magnesio co- micronizados a la humedad. También se describe una composición hecha por este método.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14184164 | 2014-09-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP17021465A true ECSP17021465A (es) | 2017-05-31 |
Family
ID=51542160
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECIEPI201721465A ECSP17021465A (es) | 2014-09-09 | 2017-04-06 | Formulación que comprende glicopirrolato, método y aparato |
Country Status (38)
Country | Link |
---|---|
US (2) | US10532041B2 (es) |
EP (2) | EP3689332A1 (es) |
JP (1) | JP6502501B2 (es) |
KR (1) | KR101927960B1 (es) |
CN (1) | CN106604720B (es) |
AP (1) | AP2017009777A0 (es) |
AR (1) | AR101793A1 (es) |
AU (1) | AU2015314272B2 (es) |
BR (1) | BR112017003888B1 (es) |
CA (1) | CA2960694C (es) |
CL (1) | CL2017000560A1 (es) |
CO (1) | CO2017003056A2 (es) |
CY (1) | CY1124569T1 (es) |
DK (1) | DK3191081T3 (es) |
DO (1) | DOP2017000065A (es) |
EA (1) | EA037332B1 (es) |
EC (1) | ECSP17021465A (es) |
ES (1) | ES2793905T3 (es) |
HR (1) | HRP20201005T1 (es) |
HU (1) | HUE049339T2 (es) |
IL (1) | IL250427A0 (es) |
LT (1) | LT3191081T (es) |
MA (2) | MA50680A (es) |
MX (1) | MX2017003080A (es) |
MY (1) | MY181647A (es) |
NZ (1) | NZ728435A (es) |
PH (1) | PH12017500303B1 (es) |
PL (1) | PL3191081T3 (es) |
PT (1) | PT3191081T (es) |
RS (1) | RS60299B1 (es) |
SG (1) | SG11201700536XA (es) |
SI (1) | SI3191081T1 (es) |
SV (1) | SV2017005403A (es) |
TN (1) | TN2017000077A1 (es) |
TW (1) | TWI602566B (es) |
UA (1) | UA115958C2 (es) |
WO (1) | WO2016038116A1 (es) |
ZA (1) | ZA201700658B (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11219602B2 (en) | 2017-03-15 | 2022-01-11 | Vectura Limited | Method for making a micronized dry powder formulation of glycopyrrolate and magnesium stearate |
CN112137957B (zh) * | 2019-06-26 | 2022-07-29 | 长风药业股份有限公司 | 一种药用吸入气雾剂及其制备方法 |
WO2021143785A1 (zh) * | 2020-01-15 | 2021-07-22 | 四川海思科制药有限公司 | 一种含茚达特罗的吸入气雾剂药物组合物及其制备方法 |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2956062A (en) | 1959-02-26 | 1960-10-11 | Robins Co Inc A H | Esters of amino alcohols |
SE9302777D0 (sv) | 1993-08-27 | 1993-08-27 | Astra Ab | Process for conditioning substances |
GB9501841D0 (en) | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
GB9808470D0 (en) | 1998-04-22 | 1998-06-17 | Smithkline Beecham Plc | Novel process and apparatus |
GB9826284D0 (en) | 1998-12-01 | 1999-01-20 | Rhone Poulence Rorer Limited | Process |
GB9826286D0 (en) | 1998-12-01 | 1999-01-20 | Rhone Poulence Rorer Limited | Process |
GB0008660D0 (en) | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
EP1274400A1 (en) | 2000-04-11 | 2003-01-15 | Dura Pharmaceuticals, Inc. | Physically stabilized dry powder formulations |
JP5033297B2 (ja) | 2000-07-20 | 2012-09-26 | カムピナ・ベスローテン・フェンノートシャップ | 結晶性の錠剤化用添加剤の製造方法、それにより得られる添加剤、およびその使用 |
NZ526059A (en) | 2000-11-30 | 2005-05-27 | Vectura Ltd | Method of making composite active particles in the presence of an additive material for use in a pharmaceutical composition |
GB0030074D0 (en) | 2000-12-08 | 2001-01-24 | Univ London Pharmacy | Particulate inhalation carrier |
DE10212264A1 (de) | 2002-03-20 | 2003-10-02 | Boehringer Ingelheim Pharma | Kristallines Mikronisat, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels |
US7309707B2 (en) | 2002-03-20 | 2007-12-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament |
ITMI20022674A1 (it) | 2002-12-18 | 2004-06-19 | Chiesi Farma Spa | Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione. |
US20040121003A1 (en) | 2002-12-19 | 2004-06-24 | Acusphere, Inc. | Methods for making pharmaceutical formulations comprising deagglomerated microparticles |
US7188993B1 (en) * | 2003-01-27 | 2007-03-13 | Harold W Howe | Apparatus and method for resonant-vibratory mixing |
GB0327723D0 (en) | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
GB0321607D0 (en) | 2003-09-15 | 2003-10-15 | Vectura Ltd | Manufacture of pharmaceutical compositions |
JO3102B1 (ar) | 2004-03-17 | 2017-09-20 | Chiesi Framaceutici S P A | صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة |
GB0409703D0 (en) * | 2004-04-30 | 2004-06-02 | Vectura Ltd | Pharmaceutical compositions |
GB0410398D0 (en) * | 2004-05-10 | 2004-06-16 | Arakis Ltd | The treatment of respiratory disease |
GB0410399D0 (en) * | 2004-05-10 | 2004-06-16 | Arakis Ltd | The treatment of respiratory disease |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
GB0425758D0 (en) | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
US20060292077A1 (en) | 2005-03-18 | 2006-12-28 | Zhao Jonathon Z | Dendritic and star-shaped contrast agents for medical devices and bioabsorbable radiopaque bulk material and method for producing same |
GB0523653D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
CA2614409C (en) | 2005-07-07 | 2014-05-20 | Nanotherapeutics, Inc | Process for milling and preparing powders and compositions produced thereby |
GB0523654D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
GB0523655D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
GB0523656D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
GB0525254D0 (en) | 2005-12-12 | 2006-01-18 | Jagotec Ag | Powder compositions for inhalation |
GB0613161D0 (en) | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
JP5283835B2 (ja) * | 2006-07-06 | 2013-09-04 | 東京エレクトロン株式会社 | マイクロ波プラズマ処理装置及びマイクロ波プラズマ処理装置用ゲートバルブ |
EP1894568A1 (en) | 2006-08-31 | 2008-03-05 | Novartis AG | Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases |
EP1944018A1 (en) | 2007-01-10 | 2008-07-16 | CHIESI FARMACEUTICI S.p.A. | Micronised particles of low-dosage strength active agents for powder formulations for inhalation |
GB0702456D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | New combination |
AU2008325290B2 (en) | 2007-11-07 | 2011-12-08 | Astrazeneca Ab | Dry powder formulations comprising ascorbic acid derivates |
CN101896165B (zh) | 2007-12-13 | 2013-07-17 | 诺瓦提斯公司 | 有机化合物 |
AU2008334543B2 (en) | 2007-12-13 | 2011-07-28 | Novartis Ag | Organic compounds |
US8235314B2 (en) | 2009-02-12 | 2012-08-07 | Linde Aktiengesellschaft | Nonequilibrium humidity control for jet milling |
KR101290893B1 (ko) | 2009-04-09 | 2013-07-29 | 노파르티스 아게 | 피롤리디늄 염의 제조 방법 |
AP3775A (en) | 2009-04-24 | 2016-08-31 | Iceutica Pty Ltd | Method for the production of commercial nanoparticle and microparticle powders |
RU2585101C2 (ru) * | 2010-04-01 | 2016-05-27 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Способ приготовления частиц носителя для сухих порошков для ингаляции |
PL2560611T3 (pl) | 2010-04-21 | 2018-05-30 | Chiesi Farmaceutici S.P.A. | Sposób wytwarzania cząstek o zredukowanych ładunkach eIektrostatycznych |
AU2011298315B2 (en) | 2010-08-31 | 2014-08-28 | Glaxo Group Limited | Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same |
US20140308214A1 (en) | 2011-02-17 | 2014-10-16 | Cipla Limited | Pharmaceutical Composition |
JO3510B1 (ar) * | 2011-03-04 | 2020-07-05 | Heptares Therapeutics Ltd | استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب |
EP2709447A4 (en) | 2011-05-17 | 2014-10-22 | Pearl Therapeutics Inc | COMPOSITIONS, METHODS AND SYSTEMS FOR RESPIRATORY ADMINISTRATION OF AT LEAST TWO ACTIVE AGENTS |
GB201205632D0 (en) | 2012-03-30 | 2012-05-16 | Vectura Ltd | Method and apparatus |
WO2014007766A1 (en) | 2012-07-05 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dry powder inhalers comprising a carrier other than lactose |
WO2014007767A1 (en) | 2012-07-05 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dry powder inhalers comprising a carrier other than lactose and a ternary component |
DE102012211907A1 (de) * | 2012-07-09 | 2014-01-09 | Robert Bosch Gmbh | Drehschlagschrauber mit einem Schlagwerk |
GB201305825D0 (en) | 2013-03-28 | 2013-05-15 | Vectura Ltd | New use |
MX2015016058A (es) | 2013-05-22 | 2016-12-20 | Pearl Therapeutics Inc | Composiciones, metodos y sistemas para el suministro por via respiratoria de tres o mas agentes activos. |
EP3082708B1 (en) | 2013-12-17 | 2019-04-03 | Merck Sharp & Dohme Corp. | Media milling process for the manufacture of active pharmaceutical ingredients in propellants |
-
2015
- 2015-09-09 TN TN2017000077A patent/TN2017000077A1/en unknown
- 2015-09-09 CN CN201580048064.1A patent/CN106604720B/zh active Active
- 2015-09-09 UA UAA201703025A patent/UA115958C2/uk unknown
- 2015-09-09 MX MX2017003080A patent/MX2017003080A/es active IP Right Grant
- 2015-09-09 KR KR1020177009495A patent/KR101927960B1/ko active IP Right Grant
- 2015-09-09 AP AP2017009777A patent/AP2017009777A0/en unknown
- 2015-09-09 WO PCT/EP2015/070660 patent/WO2016038116A1/en active Application Filing
- 2015-09-09 RS RS20200579A patent/RS60299B1/sr unknown
- 2015-09-09 US US15/509,769 patent/US10532041B2/en active Active
- 2015-09-09 BR BR112017003888-9A patent/BR112017003888B1/pt active IP Right Grant
- 2015-09-09 MY MYPI2017700336A patent/MY181647A/en unknown
- 2015-09-09 SG SG11201700536XA patent/SG11201700536XA/en unknown
- 2015-09-09 EP EP20165232.8A patent/EP3689332A1/en active Pending
- 2015-09-09 JP JP2017532216A patent/JP6502501B2/ja active Active
- 2015-09-09 PT PT157625955T patent/PT3191081T/pt unknown
- 2015-09-09 PL PL15762595T patent/PL3191081T3/pl unknown
- 2015-09-09 CA CA2960694A patent/CA2960694C/en active Active
- 2015-09-09 SI SI201531220T patent/SI3191081T1/sl unknown
- 2015-09-09 NZ NZ728435A patent/NZ728435A/en unknown
- 2015-09-09 AU AU2015314272A patent/AU2015314272B2/en active Active
- 2015-09-09 EP EP15762595.5A patent/EP3191081B1/en active Active
- 2015-09-09 ES ES15762595T patent/ES2793905T3/es active Active
- 2015-09-09 TW TW104129823A patent/TWI602566B/zh active
- 2015-09-09 MA MA050680A patent/MA50680A/fr unknown
- 2015-09-09 DK DK15762595.5T patent/DK3191081T3/da active
- 2015-09-09 MA MA40617A patent/MA40617B1/fr unknown
- 2015-09-09 HU HUE15762595A patent/HUE049339T2/hu unknown
- 2015-09-09 LT LTEP15762595.5T patent/LT3191081T/lt unknown
- 2015-09-09 AR ARP150102874A patent/AR101793A1/es not_active Application Discontinuation
- 2015-09-09 EA EA201790544A patent/EA037332B1/ru unknown
-
2017
- 2017-01-26 ZA ZA2017/00658A patent/ZA201700658B/en unknown
- 2017-02-02 IL IL250427A patent/IL250427A0/en active IP Right Grant
- 2017-02-17 PH PH12017500303A patent/PH12017500303B1/en unknown
- 2017-03-07 SV SV2017005403A patent/SV2017005403A/es unknown
- 2017-03-08 DO DO2017000065A patent/DOP2017000065A/es unknown
- 2017-03-08 CL CL2017000560A patent/CL2017000560A1/es unknown
- 2017-03-29 CO CONC2017/0003056A patent/CO2017003056A2/es unknown
- 2017-04-06 EC ECIEPI201721465A patent/ECSP17021465A/es unknown
-
2019
- 2019-12-03 US US16/701,616 patent/US20200155506A1/en not_active Abandoned
-
2020
- 2020-06-17 CY CY20201100560T patent/CY1124569T1/el unknown
- 2020-06-25 HR HRP20201005TT patent/HRP20201005T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2020002269A1 (es) | Anticuerpo que se une a redil33; polinucleótido; vector; célula hospedadora; método para producir el anticuerpo; composición farmacéutica; producto de combinación; uso del anticuerpo para tratar una afección inflamatoria (divisional de la solicitud no. 201702433) | |
CL2016001587A1 (es) | Derivado basado en 1,2-naftoquinona y método de preparación del mismo. | |
CL2016002877A1 (es) | Compuestos de 2-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y métodos de uso de los mismos. | |
JP2017500760A5 (es) | ||
CO2017002472A2 (es) | Formulación de acetato de abiraterona | |
CL2015001772A1 (es) | Composición farmacéutica para el tratamiento de dolor cabeza, y método de preparación de la misma. | |
EA201692043A1 (ru) | Лекарственная форма иммунодепрессанта | |
BR112016028316A2 (pt) | composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamento | |
BR112017006779A2 (pt) | composição farmacêutica oral de baixa dose seu processo de preparação e método de tratamento | |
CO2019003424A2 (es) | Extracto de planta impregnado de alulosa y método de preparación para el mismo | |
BR112017003581A2 (pt) | borracha natural resistente à oxidação e um método para sua produção | |
ECSP17021465A (es) | Formulación que comprende glicopirrolato, método y aparato | |
CL2016001763A1 (es) | Antagonistas selectivos de nr2b | |
BR112016028083A2 (pt) | Composição oral farmacêutica de isotretinoina e seu processo de preparação | |
BR112017001963A2 (pt) | composição farmacêutica oral, seu processo de preparação e método de tratamento | |
BR112017009848A2 (pt) | combinação, composição farmacêutica, kit, e, método para preparar uma composição farmacêutica. | |
CL2019003571A1 (es) | Lipido que comprende ácido docosapentanoico. (divisional solicitud 3351-2016) | |
RU2014154366A (ru) | Применение пробиотического штамма микроорганизма enterococcus faecium l3 для лечения нейродегенеративных заболеваний | |
ES2501367B1 (es) | Método de tratamiento de coccidiosis | |
FR3023718B1 (fr) | Compositions pharmaceutique et/ou cosmetique decontaminees par haute pression | |
FR3026009B1 (fr) | Nanocapsules lipidiques, compositions pharmaceutiques, procede de preparation, et utilisations correspondants | |
ECSP16086746A (es) | Formulación inmunosupresora | |
BR112018009807A8 (pt) | processo para preparar uma formulação de pó seco que compreende um anticolinérgico, um corticosteroide e um beta-adrenérgico | |
BR112017007589A2 (pt) | processo para preparar um ingrediente farmacêutico ativo inalável, ingrediente farmacêutico ativo inalável e formulação farmacêutica inalável | |
PE20151500A1 (es) | 4-(4-ciano-2-tioaril) dihidropirimidinonas y su uso |